Latest Headlines

Latest Headlines

Novartis tests performance pricing for much-anticipated Entresto launch

Novartis has big plans for its much-anticipated heart failure remedy Entresto. The Swiss drugmaker figures it can parlay impressive trial data on the drug into its biggest launch in years--perhaps ever.

No artful tax dodging here, drug firms tell Australia transfer-price inquiry

We checked and everything is done correctly on our tax obligations, 9 drug companies said in separate submissions ahead of testimony on July 1 to an Australian Senate inquiry on tax avoidance.

Novartis shells out $200M-plus for Spinifex and its mid-stage pain drug

Novartis snapped up tiny Spinifex and its mid-stage pain drug in a $200 million-plus deal.

Novartis puts Cosentyx on track for $4B-plus with new psoriatic arthritis data

With competitors hot on its trail in the next-gen psoriasis drug market, Novartis is looking to build out the list of indications for its up-and-comer, Cosentyx. And with an eye on that goal, it just scored a boost in psoriatic arthritis, one of two label expansions it's filed for with the FDA.

India's Gujarat state drugmakers speed up biosimilar race

Drug companies in India's leading industrial state of Gujarat, the base of Prime Minister Narendra Modi, are stepping up efforts to crack the domestic market for biosimilars as well as abroad, Business Standard reports.

Novartis pays up to $700M for novel pain treatment developer Spinifex

Swiss-based Novartis will buy privately-held Spinifex Pharmaceuticals for $200 million upfront as well as unspecified clinical and milestone payments for a firm that developed a candidate for neuropathic pain, EMA401, a novel angiotensin II Type 2 receptor (AT2R) antagonist.

Novartis scores recommendation from EMA for myeloma drug Farydak

After scoring FDA approval earlier this year, Novartis' multiple myeloma med Farydak (panobinostat) is picking up steam across the pond, snagging the European Medicines Agency's (EMA) recommendation for patients with advanced forms of the disease.

Unions accuse Novartis of 'sham' patent fight to delay Sun's Gleevec generics

Two union funds are suing Novartis, claiming that the Swiss drugmaker used "sham" patent-infringement claims to delay a generic version of its blockbuster leukemia drug Gleevec. Though just the latest in a series of legal battles over drug patent settlements, it's the first attempt by purchasers to block one of those settlements, the plaintiffs' lawyers said.

Novartis playing catch-up in cancer? Not us, says top oncology exec

Novartis may be trailing behind Big Pharma rivals that already have immuno-oncology treatments on the market. But the company insists that doesn't mean it's not well positioned in oncology.

Biosimilar of Novartis' eye drug Lucentis launched in India

Novartis' eye drug Lucentis has long had a target on its back from biosimilar makers who would love to get some piece of the $4 billion in annual sales it racks up. Now an Indian drugmaker says it has hit that mark.